Posts Tagged ‘Josep M. Llovet’

Thursday April 12th, 2018

Hospital Clínic and IDIBAPS researchers participate in the new European clinical guidelines for the management of hepatocellular carcinoma

Two researchers from the Hepatic Oncology Unit at Hospital Clínic-IDIBAPS have participated in the development of the new clinical practice guidelines for the management of hepatocellular carcinoma developed by the European Association for the Study of the Liver (EASL). It is a consensus document that marks the road map in the diagnosis, treatment and monitoring of this type of cancer, which accounts for 90% of primary liver tumors. Read the rest of this entry »

Comments Closed

Categories

Posted in:

Friday March 31st, 2017

IDIBAPS hosts the meeting of the HEP-CAR european project on hepatocarcinoma and co-morbidities

On 13 March, IDIBAPS hosted the annual meeting of the European HEP-CAR consortium. The aim of the project is to identify the molecular mechanisms involved in the development of hepatocellular carcinoma (HCC) and their role in the different co-morbidities that induce the onset of this type of cancer: the infection by hepatitis B and C viruses, alcohol intake or obesity. Translational Reserarch in Hepatic Oncology IDIBAPS group, led by Dr. Josep M. Llovet, in collaboration with Dr. Roser Pinyol and 8 more researchers, participates in this research intiative.
Read the rest of this entry »

Comments Closed

Categories

Posted in:

Thursday October 13th, 2016

The “Handbook of Translational Medicine” has been published

The distribution of the “Handbook of Translational Medicine” began last week. Dr. Josep M. Llovet, ICREA professor at IDIBAPS-Hospital Clínic and director of the Master in Translational Medicine at the University of Barcelona, is the manual’s editor and several professionals from Clínic Campus have collaborated. The aim of the book is to summarize the basic concepts of translational medicine, defined as the discipline that transfers the knowledge and discoveries generated by basic research in biomedical sciences into clinical practice.
Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday September 27th, 2016

IDIBAPS researchers identify a new therapeutic target for liver cancer

IDIBAPS researchers have identified the first epi-driver in liver cancer, a type of epigenetic alteration in the IGF2 gene that causes tumors to grow. In the study, published in the Gastroenterology journal, they have found that this alteration occurs in 15% of tumors and that a monoclonal antibody can effectively block it and slow tumor progression in animal models. Dr. Josep M. Llovet, ICREA Professor, Head of the Translational research in hepatic oncology IDIBAPS group and Director of the Mount Sinai Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York), has coordinated this study. The first authors of the article are Iris Martínez-Quetglas and Roser Pinyol, researchers at the same team.

Read the rest of this entry »

Comments Closed
Friday January 15th, 2016

Four researchers at Hospital Clínic and IDIBAPS among the 2015 most cited scientists

Dr. Jordi Bruix, Head of the hepatic Oncology Unit at Hospital Clínic de Barcelona, the Hepatic Oncology IDIBAPS research team, the Barcelona Clinic Liver Cancer (BCLC) and scientific director of CIBEREHD; Dr. Josep Dalmau, ICREA Professor and Head of the Pathogenesis of autoimmune neuronal disorders IDIBAPS research group; Dr. Josep Maria Llovet, ICREA Professor, Head of the Translational research in hepatic oncology research group at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York); and Dr. Eduard Vieta, head of the Psychiatry and Psychology Department at Hospital Clínic and leader of Bipolar Disorders team at IDIBAPS, are among the most influential names in science and appear in the Highly Cited Researchers 2015 list published by Thomson Reuters.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday September 22nd, 2015

IDIBAPS participates in a 5.7M European project to improve knowledge on liver cancer

The Translational Reserarch in Hepatic Oncology IDIBAPS group, led by Dr. Josep M. Llovet, in collaboration with Dr. Roser Pinyol and 8 more researchers, participates in a European project to identify the molecular mechanisms that have a direct impact on the development of hepatocellular carcinoma (HCC). The HEP-CAR project will evaluate the role of these mechanisms in different liver diseases leading to HCC -the infection by hepatitis B and C, overweight or alcohol-. This research initiative, coordinated by the University of Freiburg and in which ten European academic centers are involved, is part of Horizon 2020, the European Comission framework programme for research and innovation, and it is endowed with a budget of 5.7 million euros, one of them corresponding to IDIBAPS.

Read the rest of this entry »

Comments Closed
Page 1 of 41234